Disodium cromoglycate in ragweed-allergic rhinitis.
This study was designed to test the effectiveness of disodium cromoglycate when compared to placebo in a double-blind study in patients with ragweed allergic rhinitis. Patients were selected on the basis of a clinical history and a 4+ reaction to the intradermal injection of water-soluble ragweed, 0.02 c.c. of 500 PNU/c.c. Active agent/placebo groups were selected at random and were on the drug for approximately 8 wk, commencing 1 wk prior to the onset of the ragweed pollen season. Patient response was evaluated using patient diary cards, number of antihistamine tablets taken, and patient interviews. In the Toronto study, of 17 patients on the active drug, 15 were graded as improved, compared to only 6 of 21 placebo-treated patients who were improved. However, in the Hamilton study, results were less impressive. Nonetheless, it appears that intranasal insufflation of disodium cromoglycate was more effective in reducing ragweed hay fever symptoms than placebo.
D002986:Clinical Trials as Topic; D004205:Cromolyn Sodium / Q000627:therapeutic use*; D003888:Desensitization, Immunologic; D004341:Drug Evaluation; D005260:Female; D006634:Histamine H1 Antagonists / Q000627:therapeutic use; D006801:Humans; D007073:Immunoglobulin E / Q000032:analysis; D008297:Male; D010919:Placebos; D010944:Plants / Q000276:immunology*; D011058:Pollen; D011863:Radioimmunoassay; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy*
D006634:Histamine H1 Antagonists; D010919:Placebos; D007073:Immunoglobulin E; D004205:Cromolyn Sodium